Meet the Investment Team


Jonathan Behr, PhD

Managing Director

Jon joined the T1D Fund from Partners Healthcare Innovation, where he was a Market Sector Leader and Executive in Residence, driving technology translation from research hospitals affiliated with Harvard Medical School. He previously held senior venture creation roles including Vice President of New Ventures for Enlight Biosciences and Principal at PureTech Ventures (LON:PRTC). Jon has co-founded and supported seven companies (including holding C-level operating, business development and board director positions) and managed alliances with top pharmaceutical companies. He earned his Ph.D. at Massachusetts Institute of Technology as a Howard Hughes fellow and his B.S. from Rice University.

Katie Ellias

Katie Ellias

Managing Director

Katie joined the T1D Fund in July 2018 from Endeavour Vision, a growth stage fund, where she focused on medical devices and digital health as Senior Investment Director. She was previously Principal at Sofinnova Partners, a leading early stage life sciences fund, investing in medical technologies. She served as Board Observer for ReCor Medical, CorWave, Shockwave Medical, RefleXion Medical, Pixium Vision, and MD Start.

Prior to VC, Katie held leadership roles at Medtronic in the Interventional Cardiology franchise. Katie holds an MBA from the Wharton School at the University of Pennsylvania and a BA in International Relations and Political Science from Yale University. She started her career at McKinsey & Company.

Board of Directors

Gina Agiostratidou

Program Director
The Leona M. and Harry B. Helmsley Charitable Trust

Dr. Gina Agiostratidou is the Program Director for the Helmsley Charitable Trust’s Type 1 Diabetes (T1D) Program, which aims to advance research, treatments, technologies, and services that improve the life of people with type 1 diabetes.

Previously, Gina was the scientific program manager at the Children’s Tumor Foundation, bringing scientists from around the globe to collaborate on research opportunities in the field of neurofibromatosis. She has completed two post-doctoral fellowships at Albert Einstein College of Medicine and Mount Sinai School of Medicine, focusing primarily on molecular biology and biochemistry.

Gina earned a PhD in Molecular Biology from the Medical School, National and Capodistrian University of Athens, Greece, and an MSc degree in Advanced Molecular Biology and Biotechnology at the University of London, UK. She has also earned her MBA from New York University, Stern Business School.

Grant Beard

Chairman & CEO
Wynnchurch Industries

Grant Beard is currently the Chairman & CEO of Wynnchurch Industries, LLC a diversified holding company investing in engineered product businesses. Wynnchurch Industries executes a buy, build and hold strategy for its operating companies.

Mr. Beard also serves as a Senior Advisor to Wynnchurch Capital and serves on the Board of Directors of TA Systems (Chairman), Advanced Energy Industries (NASDAQ, Chairman), and U.S. Manufacturing Corporation. Prior to joining Wynnchurch Industries, Mr. Beard served as CEO of numerous industrial companies. He serves on the JDRF International Board of Directors.

Timothy Clark

former CIO
CarVal Investors

Tim Clark is the President and CEO of TreeHouse, a faith-based mentoring organization focused on empowering at-risk youth. TreeHouse’s mission is to bring living hope to hurting youth and families leading to life transformation. Tim is building TreeHouse into a national model for communities to empower at-risk youth.

Prior to joining TreeHouse, Tim was the CEO of Urban Ventures, a unique and influential inner city non-profit providing multi-cultural holistic family, education, and employment programming. Prior to joining Urban Ventures, Tim worked for CarVal Investors, a global alternative investment manager and a subsidiary of Cargill. He joined the firm in 1992, and has experience investing in a wide variety of alternative and credit related asset classes across the globe. When Tim retired from CarVal in 2012, he was Chief Investment Officer, Senior Partner and Executive Team Member, sitting on all investment committees and also responsible for over 150 institutional investor relationships. He serves on the JDRF International Board of Directors, as well as various other for-profit and non-profit Boards and Investment Committees.

Sean Doherty (chair)

Managing Director and General Counsel
Bain Capital

Sean Doherty is a Managing Director and the General Counsel of Bain Capital, a private investment firm in Boston which he joined in 2005. He serves on the JDRF International Board of Directors and has been a JDRF volunteer since 2002, when his son Finn was diagnosed with T1D. He served on JDRF’s New England Chapter board from 2004-2016 and was its president from 2014-2016..

Mr. Doherty served from 1990 to 1994 as an officer in the U.S. Navy aboard a guided-missile frigate during deployments to the Persian Gulf and Central America. He received a B.A. magna cum laude from Harvard College and a J.D. magna cum laude from Harvard Law School. After law school, Mr. Doherty clerked for a federal judge in Boston and was an attorney at Ropes & Gray. He lives in Cohasset, Massachusetts, with his wife Suzy and their two teenagers.

Karen Jordan

Board Director
JDRF International

Karen Jordan serves on JDRF’s International Board and the T1D Fund Board. She also serves as President of JDRF’s Greater Bay Area Chapter Board and previously served on the Silicon Valley Branch Board. She is a member of JDRF’s Research Committee. She is a founding board member of Carb DM, a non-profit providing education and support services to the T1D community, and is the organizer of the Bay Area Diabetes Consortium, comprised of 22 organizations serving the diabetes community in California’s greater Bay Area.

Her previous non-profit work includes service on different boards including, among others, Starlight Children’s Foundation, Stanford GSB Alumni Association and the Portola Valley School District. She was a member of the group who founded Summit Prep, a charter school profiled in Waiting for Superman. She also serves on the Stanford Healthcare Community Council.

Karen earned her B.A. in Economics-Business from UCLA and her MBA from the Stanford University GSB. She has also completed TPW’s year-long program on strategic philanthropy. She has worked as an investment banker and with the Mayor’s Office in Los Angeles.

Stephen Newman

former COO
Tenet Healthcare

Stephen L. Newman, M.D. has served in a number of senior leadership roles at Tenet Healthcare Corporation including Vice Chairman, Chief Operating Officer, Executive Vice President and Chief Executive Officer, Tenet California. Before joining Tenet, Dr. Newman held executive positions at Columbia/HCA, Inc. and served as Senior Vice President and Chief Medical Officer of Touro Infirmary in New Orleans. Prior to 1990, Dr. Newman was an Associate Professor of Pediatrics and Medicine at Wright State University School of Medicine, and Director of Gastroenterology and Nutrition Support at Children’s Medical Center in Dayton, Ohio. Dr. Newman is Chair of the JDRF Research Committee and also serves on the JDRF Executive Committee. Dr. Newman is currently a Strategic Advisor at Gryphon Investors, a member of the board of directors of Zavante Therapeutics Inc. and CentraForce, LLC.

Derek K. Rapp

President and CEO

Derek Rapp is President and Chief Executive Officer of JDRF. Prior to his appointment in 2014, Derek served as Vice-Chairman of the Board of Directors for JDRF International and was JDRF Research Committee Chair. He has been involved in the research funding and oversight activities of JDRF since 2005.

From early 2001 until February 2011, Derek was Chief Executive Officer of Divergence, Inc., a venture-backed biotech company finding solutions in the prevention and control of pest infections. He led the successful sale of the company in February 2011. As CEO of Divergence, Derek’s main responsibilities included developing and implementing the company’s strategy, ensuring suitable financing of the company, implementing relationships with licensees and collaborators, and overseeing operations.

Find Out More

Contact Amy Montalto, National Director,
to discover how to be a part of the T1D Fund | 617-910-7542